An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2020
Price : $35 *
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 30 Jun 2019 Planned End Date changed from 24 Oct 2023 to 1 Nov 2023.
- 14 Dec 2018 Planned End Date changed from 27 Sep 2023 to 24 Oct 2023.
- 04 Oct 2018 Planned End Date changed from 18 Jul 2023 to 27 Sep 2023.